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Abstract 
The increase in bacterial resistance to
antimicrobials has motivated researchers to
develop experimental animal models to inte-
grate pharmacokinetic/pharmacodynamic (PK/
PD) profiles to predict the effectiveness of
antimicrobials treatments. The models used to
date have a weakness based on the use of the
minimum inhibitory concentration (MIC),
whose value is obtained only in vitro, deter-
mined under constant conditions with an
exponential error, regarding to the double dilu-
tion used. The aim of this study was to develop
and validate a device for subcutaneous implan-
tation, which can be applied in any animal
species, allowing simultaneous description of
in vivo bacterial killing curve and pharmacoki-
netic profile of the drug under study. Based on
the obtained results, it can be concluded that
the use of this model will allow researchers to
apply PK/ PD decreasing the error originated in
the use of MIC as a measure of antimicrobial
pharmacodynamics.
Introduction
In the last decades, the emerging growth of
bacterial resistance to antimicrobials has been
studied extensively. Overuse and/or irrational
use of antimicrobials favoured the selection of
resistant microorganisms; this resistance may
extend to other microbial populations, threat-
ening humans and animals, including those
not previously exposed to antimicrobial
agents.1,2 In many bacterial infections, the goal
of the antimicrobial therapy is not only to
ensure clinical cure but to also achieve bacter-
ial eradication (bacteriological cure).3 In this
context, Toutain et al.4 emphasize the so-called
Pollyanna phenomenon, which refers to the
lack of correlation between clinical cure and
bacteriological cure and the consequences of
assessing antimicrobial efficacy in sympto-
matic responses exclusively.
The effect of an antimicrobial treatment is
the result of a dynamic three-way interaction
between the host, the drug, and the infecting
organism.5
Pharmacokinetics describes the links
between the drug and the host, while pharma-
codynamics describes the links between the
drug and the bacteria. It is important to high-
light that a proper pharmacokinetic/pharmaco-
dynamic (PK/PD) study should include a third
component, the interaction between the host
and the pathogen.4
The three PK/PD indices used as efficacy
predictors relates different aspects of the con-
centration-time curve to the minimum
inhibitory concentration (MIC): time
(T>MIC), peak of the curve (Cmax/MIC), and
the integrate of time and concentration calcu-
lated as area under the curve (AUC/MIC).6,7 All
of these indices use MIC for correlating phar-
macokinetics with potency. Although MIC is
the simplest and most widely used measure of
the intrinsic activity of antimicrobials, its use
in the present situation is questionable. 
Minimum inhibitory concentrations are
generally determined by use of two-fold dilu-
tions of the antimicrobial drug. The true MIC
is mostly not the figure determined but is in
between the observed MIC and the next lower
dilution. The inherent error is one dilution
step in either direction.8 Evidently, this impre-
cision may have a profound influence for the
calculated PK/PD indices. On the other hand,
in an infectious disease, there is a population
of bacteria involved and not individual bacte-
ria; therefore, it is important to know the dis-
tribution of the antimicrobial susceptibility of
this population.9 Also by using MIC as pharma-
codynamic parameter for evaluation of antimi-
crobial potency, any information related to the
interaction between host and bacteria is
unknown and impossible to be established.9
In the last years a number of experimental
models for PK/PD studies have been reported;
some of them are in vitro models, such as, the
kinetic models of dilution or diffusion that
simulate the clearance of drug from the sys-
tem.10,11 There are also models of specific dis-
eases that use fibrin clots or glass beads to
simulate endocarditis or devices related infec-
tions, such as the one reported by McGrath et
al.12 These models are informative since they
allow the description of the effect of defined
concentration-time profiles of a drug on select-
ed bacterial strains in a controlled and repro-
ducible environment.13 Different aspects of
PK/PD relationships, including selection of
resistance, can be studied and have critical
factors identified. These models are good tools
for studies on most aspects of PK/PD relation-
ships of antimicrobials. However, they are
affected by the same factors as MIC determina-
tions (e.g. medium, growth phase of inoculum
and its density), and do not account for effects
of the interaction between the host and the
infecting organism.
Another model used to study PK/PD is the ex
vivo infection model; this consists of subcuta-
neous implantation tissue cages in animals,
which can be stimulated by irritants, such as
carrageenan to obtain exudate. The experi-
mental animals are treated with an antimicro-
bial, and the exudate samples obtained are
confronted ex vivo with standardized bacterial
cultures in order to quantify the antibacterial
activity over an incubation period of 24 hours.
This model allows the calculation of AUC/MIC
(AUIC) 24 for bacteriostasis (no change in
bacterial counts), bactericidal activity (99.9%
reduction in the number of bacteria), or total
bacterial eradication.14 Like the in vitro mod-
els, ex vivo models do not include the host
defense mechanisms.
Finally, different in vivo infection models
have been designed; these models include
experimental infections in small rodents such
those reported by Zak and O'Reilly15 and Andes
and Craig.16 These models are either general
(thigh infections, peritonitis-septicemia) or
reflect more specific disease conditions (pneu-
monia, meningitis, endocarditis, pyelonephri-
tis, abscesses, foreign-body infections etc).17
Each model has its own limitations; there are
general factors that affect the conclusions, such
as choice of bacterial strains, inoculum size,
time between infection and treatment and dos-
ing regimen.15 The main weakness of these
models is the difference in pharmacokinetics
between small rodents and larger animals. This
can be solved, to some extent, through dose
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fractionation or prolongation of the elimination
rate through, e.g., renal impairment. Also, the
animals are often rendered neutropenic before
infection, which nullifies the effect of the host
defences. The present study presents a novel in
vivo model. This model is designed to allow the
bacteria growing and the transfer of free drug
(not bound to plasma proteins) from the vascu-
lar space into the device and vice versa but pre-
vents bacteria from leaking. In this article, the
model is described and validated using a time-
dependent antimicrobial administered intra-
venously with two administration designs, emu-
lating differing therapeutic situations (a




Bacterial strain and inoculum preparation
Escherichia coli ATCC25922, was used in all
experiments. It was kept at -20°C in a tryptic
soy broth with glycerol as cryoprotectant.
Immediately prior to start of each experiment,
an inoculum was prepared from a culture
grown for 18h on Mueller Hinton agar. The cul-
ture was suspended in PBS to an approximate
concentration of 1¥108 cfu/mL (0.5McFarland
scale).
Preparation of subcutaneous implanted
devices (SID)
The devices consisted of polypropylene cap-
sules of 12 mm of diameter by 10 mm of depth,
with a 9 mm gap (Figure 1). A total of thirty-six
SID were used. Thirty-two were filled with 
100 µL of E. coli inoculum diluted on 200 µL of
Brain Heart broth, to a final concentration of
1¥105. Once filled, the gap was closed with a
0.24 µm Millipore membrane adhere to the gap
with methyl cyanoacrylate and reinforced with
polypropylene rings sealed by hot melt.
The remaining four SID (not inoculated)
were filled in, with 300 µL of PBS/Brain Hearth
broth (33/66), and used to evaluate both tissue
reactions at the implantation site and the
effect of incubation on the physicochemical
characteristics of the content.
Experimental animals
Six 45-day-old male New Zealand White rab-
bits (3.0 to 3.5 kg each) were used.
The animals were kept in cages of 50 cm
¥50 cm¥60 cm and fed with a commercial diet
(Gepsa Feeds, Pilar Group, RabbitHome Type).
Food and water were given ad libitum. All ani-
mal procedures were approved by the
Institutional Animal Care and Use Committee,
School of Veterinary, University of La Plata,
Argentina. 
Subcutaneous devices implantation in rab-
bits/incubation at 37°C
E. coli inoculated SID were split. Sixteen
were placed in to test tubes containing 5 mL of
brain heart broth and taken to an incubator at
37°C. The remaining 16 were surgically
implanted in 4 rabbits under anaesthesia (ket-
amine 25 mg/kg and xylazine 1 mg/kg).
Analgesia was assured by the intramuscular
administration of buprenorphine at a dose rate
of 0.05 mg/kg. Two SID were prepared as
described but, filled with PBS/Mueller Hinton.
These devices were implanted in 2 rabbits and
considered as negative controls. The day
before the study, the dorsal hair of all the rab-
bits was cut with scissors and, shortly before
the start of the study, shaved. The implantation
site (dorsal line) was disinfected with povi-
done iodine, and four subcutaneous pockets
were created. One SID was placed into each
subcutaneous pocket. Afterwards, the inci-
sions were sutured with nylon. At this time
(recorded as time 0), SIDs into test tubes con-




Devices were aseptically removed from the
site of implantation or incubator, simultane-
ously, at 12, 24, 48 and 72 hours post-implanta-
tion/incubation. For the extraction of the
implanted SID, rabbits were sedated with ace-
promazine at a dose rate of 1 mg/kg IM and
regional nerves blockade (0.1-0.2 mL of 2%
lidocaine at each site, Lidocaine®, Richmond
Vet Pharma, Argentina) for analgesia. At each
sample time, after removing SID, swabs of the
subcutaneous pocket were taken to check the
proper closing of the device. The extracted SID
were opened with sterile forceps and scissors,
and 100 uL of transudate was recovered.
Transudate bacterial number was estimated by
dilution and plating technique and expressed
in cfu/mL.
The SID filled with PBS/MuellerHinton
broth were extracted at 24 and 72 hours post-
implantation, and a biopsy of the subcuta-
neous pocket tissue was sent to the Laboratory
of Pathology, of the School of Veterinary
Sciences of the National University of La Plata
for histopathological studies. Physicochemical
and biological features of the recovered liquid
were evaluated by classical methods.18
Model validation
In order to validate the model, the antimi-
crobial effect of cephalexin (a b-lactam with
time-dependent killing kinetics) administered
intravenously using a single dose and a repeat-
ed dose schedule was studied. A total of 96SID
were prepared as previously explained but
alternatively used Staphylo coccus aureus ATCC
25923 as test strain. Immediately prior to start
of each experiment, an inoculum was prepared
from a culture grown for 18 hours on Mueller
Article
Figure 2. Time profile of bacterial growth (cfu/mL) into devices
subcutaneously implanted in rabbit (■) and incubated at 37ºC
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Hinton agar. The culture was suspended in iso-
tonic saline solution to an approximate con-
centration of 1¥108 cfu/mL (0.5 McFarland),
and then it was re-diluted to yield a final inocu-
lum of approximately 1¥105 cfu/mL. Sixteen
45-day-old male New Zealand White rabbits
(3.2 to 3.8 kg) were used. Devices were surgi-
cally implanted (six in each animal) as previ-
ously described. Twenty-four hours after sur-
gery, animals were divided into four groups, as
follows: 
- Group 1 (n=4) received cephalexin intra-
venously at a dose rate 10 mg/kg, registering
the end of administration as 0 time.  
- Group 2 (n=4) received a total of four 2.5
mg/kg intravenous doses of cephalexin
every 6 hours.
- Groups 3 (n=4) and 4 (n=4) received no
antimicrobial treatment and were used as
control for groups 1 and 2, respectively.
One of the implanted devices and a blood
sample were withdrawn from groups 1 and 3 at
3, 6, 9, 12, 18 and 24 hours post-administration
and at 0.5, 1, 3, 6, 9 and 24 hours post-admin-
istration for the remaining groups.
Blood samples were withdrawn through a 24
G (Abbocat) catheter placed in the marginal
ear vein. Devices were removed and processed
as previously described. 
Cephalexin plasma concentrations were
quantified by microbiological method using
Microccocus luteus ATCC 9341 as a microor-
ganism test.19
The procedures for viable bacteria counts
were as described previously.
Individual cephalexin concentration vs. time
curves were analyzed by non-linear least
square regression analysis using PCNonlin
(SCI Software, 4th Edition, 1992, Lexington,
USA). Initial estimates were determined using
the residual method20 and refitted by non lin-
ear regression. The number of exponents
needed was determined by applying the
Schwartz and Akaike criterions21,22 and the
residual distribution around the estimated
concentrations. Most pharmacokinetic param-
eters were calculated using classic equations
associated with compartmental analysis.20
Results
Physicochemical characteristics of the con-
tent recovered from non-inoculated SID shown
similarities to transudate: low protein content,
low specific gravity (<1.012), and absence of
nucleated cells.
Histopathological studies of implant area
did not show signs of local inflammation. All
cultures from swabs collected from subcuta-
neous pockets showed no bacterial growth
indicating a proper closure of the SID.
Bacterial growth curves in both rabbit
implanted-SID and incubated-SID showed a
proper and comparable bacterial growth. The
peak growth was observed at 24 h in both the
implanted and incubated-SID (Figure 2). No
statistically significant differences were
observed when areas under the curve (AUC)
cfu/mL vs time from incubated and implanted
SID were compared (P=0.27).
Cephalexin plasma concentration curves
and bacterial growth curves from implanted
SID for both administration schedules are pre-
sented in Figures 3 and 4. Cephalexin plasma
concentration vs time curves after single and
repeated intravenous administration were best
fitted to an open monocompartmental model in
all the animals; the following equation was
used:
C(t) = Cp exp(-K.t)
where C(t) (μg/mL) represents cephalexin
plasma concentration at t time; Cp (μg/mL) is
the concentration extrapolated to time 0 of the
first phase of cephalexin plasma disposition
and K (per h) is the elimination slope.
The average equation for the model was:
Monodose                   Cp = 5.87 e-0.06t
Repeated dose             Cp = 1.63 e-0.08t
Estimated pharmacokinetic parameters are
shown in Table 1. 
After intravenous administration of
Article
Figure 4. Mean and SD cephalexin plasma concentration (▲) and bacterial growth into
SID (■) time profile after its repeated intravenous administration at a dose rate of 2.5
mg/kg/ 6h to rabbits (n=4).
Figure 3. Mean and SD cephalexin plasma concentration (▲) and bacterial growth into











[page 48] [Veterinary Science Development 2012; 2:e10]
cephalexin following a monodose schedule
bacterial counts curves had very low inter-ani-
mal variation. Bacterial growth curves had a
similar time profile in all experimental ani-
mals, with a 2 log drop in bacterial counts at
early times followed by a significant re-grow-
ing at 24 hours post-administration. This pro-
file fits very well to the cephalexin plasma con-
centration vs time (Figure 3).
In the multi-dose intravenous administration
schedule, bacterial growth curves were similar
for all the experimental rabbits; however, varia-
tion was slightly higher than that recorded for
the single dose study. Bacterial count drop more
slowly than after single dose administration, in
concordance to time required for cephalexin
plasma concentration to achieve a steady state.
Once steady state is achieved bacterial count
dropped two log, without re-growth through the
end of the study (Figure 4).
Discussion 
In the last two decades, a number of experi-
mental in vivomodels for studies of dose/effect
relationships of antimicrobials have been
reported.16 All of these have advantages and
disadvantages, with outcomes that should be
interpreted accordingly.15,23 A model for studies
on PK/PD relationships should, ideally, enable
a detailed description of the pharmacokinetics
of the drug, the pharmacodynamic effect on
bacteria, and preferably also of the host contri-
bution to the measured effects, allowing for
the calculation of optimal doses and rational
dosing schedules.5,24,25
The model described here allows for repeat-
ed sampling and quantification of the effect of
any antimicrobial in presence of host-defence
system. Compared to the tissue cage models,
such as, the ones described by Clarke26 and
Greko,27 the present model does not induce
any systemic sign of infection. This may be
due to the proper closure system of the device,
where there was no local tissue reaction on the
implantation zone. Therefore, the safety of the
experimental animals is not affected.
The developed model has shown robustness
for differentiating the efficacy of different dos-
ing schedules. As for the single-dose studies,
they showed that bacterial growth decreased
when cephalexin concentration was high in
the early hours of the trial. After 12 hours, the
fall of cephalexin plasma concentrations lead
to an increase of bacterial growth, which
exceeded the initial inoculum.
Moreover, the administration of cephalexin
at a dose rate of 2.5 mg/kg every 6 hours inhib-
ited bacteria growing slower than after the sin-
gle dose. This is probably related to the time
required for cephalexin plasma concentrations
to reach steady state. Once this is accom-
plished, the bacterial count dropped from 107
to 105 cfu/mL, without increasing. It is impor-
tant to highlight that at the end of the study
eradication was not observed; this is some-
what unexpected as cephalexin, being a beta-
lactam, is considered time dependent bacteri-
cidal.28 An explanation for this unexpected
result could be the presence of biofilm inside
the device, which has a much higher MIC than
the bacteria in planktonic state. Although, the
Staphylococcus strain used in the present
study starts growing as biofilm after 48 hours
of implantation (unpublished observation). A
second explanation could be related to the
presence of a number of bacteria on stationary
phase. These bacteria are defined as persis-
ters.29 Persisters represent a small subpopula-
tion of cells that spontaneously enter a dor-
mant, non dividing state. When a population is
treated with a bactericidal antibiotic, regular
cells die, whereas persisters survive. In order
to kill, betalactams require active targets,
which could explain the observed tolerance.
To conclude, it can be stated that the appli-
cation of this model will enable interested
researchers to describe in vivo effects of
antimicrobials and to apply PK/PD model. This
model will be applicable for studying any
antibiotic, against any bacteria (planktonic or
biofilm) in any animal species, leading to the
design and/or the selection of rational and
individual dosing regimens.
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